Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests how well the combination of futibatinib and durvalumab given before cystectomy works in treating patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based therapy. Cisplatin-based therapy is the standard of care for patients with MIBC. However, many patients cannot receive standard therapy due to poor renal function, peripheral neuropathy, poor functional status, or clinically significant heart failure. Futibatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Radical cystectomy is a surgery to remove all of the bladder as well as nearby tissues and organs. Giving futibatinib in combination with durvalumab before surgery may be an effective treatment option for patients with MIBC who are ineligible for cisplatin-based therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wyrażenie zgody na udział w badaniu.
- •Wiek od 18 lat.
- •Masa ciała powyżej 30 kg.
- •Badanie wykazało specyficzne zmiany w komórkach raka (FGFR1, 2 lub 3).
- •Ogólny stan zdrowia pozwalający na udział w badaniu.
- •Potwierdzony rak pęcherza naciekający mięśnie.
- •Choroba w określonym stadium zaawansowania (T2-T4a, N0, M0).
- •Niezdolność do przyjęcia chemioterapii z platyną lub odmowa jej przyjęcia.
✗ Disqualifies
- •Niezdolność do poddania się planowanemu zabiegowi usunięcia pęcherza.
- •Poważne problemy z nerkami.
- •Znaczna utrata słuchu lub uszkodzenie nerwów obwodowych.
- •Poważne problemy z sercem.
- •Pacjentki w ciąży lub karmiące piersią.
- •Kobiety i mężczyźni niechętni stosowaniu skutecznej antykoncepcji.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 1, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
University of Michigan Comprehensive Cancer Center
Ann Arbor, United States
Cleveland Clinic Taussig Cancer Center
Cleveland, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
Trial contact
The Ohio State Comprehensive Cancer Center
Rebecca Williams
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/2/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.